Review Article | Volume 1 Issue 1 (2025) | Published in 2025-06-21
Evaluation of the prevalence of phenylketonuria among screened and un screened children in Baghdad
-
Abstract
Background: A congenital genetic condition known as phenylketonemia (PKD) is defined by a malfunction in the metabolism of the amino acid phenylalanine. Delays in diagnosis and treatment can result in mental and developmental problems, making it a serious health concern.
Objective: The purpose of the study was to compare children with PKD who were screened against those who were not in order to assess the efficacy of early screening programs.
Methodology: A descriptive analytical approach was used to collect patient data during 2021 and 2022.
Data included age at diagnosis, sex, geographic distribution, developmental outcomes, and follow-up. A 95% confidence level was applied and a P value of <0.05 was used.
Results: The findings demonstrated statistically significant variations in the average age of diagnosis between screened and unscreened children, with the former having an average age of two months and the latter between 15 and 36 months.
Additionally, the children who were screened at diagnosis were older (49 months) than the children who were not screened (24 and 40 months).
The children who were not screened experienced issues like epilepsy, delayed walking, and mental impairment, while the majority of the screened children were female.
Additionally, half of the individuals had a family history of the condition, especially among siblings, indicating a strong familial component to the illness.
Conclusion: In order to improve treatment outcomes and the quality of life for individuals with phenylketonuria, early screening is essential for minimizing developmental and mental difficulties brought on by delayed diagnosis. -
References
(1) Prepok, F. F., Schnabel, K. K., Sumánszki, C., Barta, A. G., Tislér, A., & Reismann, P. (2024). Long-term renal function in adult patients with phenylketonuria. Nephron, 148(4), 195-203.
(2) Cannet, C., Bayat, A., Frauendienst-Egger, G., Freisinger, P., Spraul, M., Himmelreich, N., ... & Trefz, F. (2023). Phenylketonuria (PKU) Urinary Metabolomic Phenotype Is Defined by Genotype and Metabolite Imbalance: Results in 51 Early Treated Patients Using Ex Vivo 1H-NMR Analysis. Molecules, 28(13), 4916.
(3) Ene, C. D., Penescu, M., Nicolae, I., & Capusa, C. (2024). The Role of the L-Arginine–Nitric Oxide Molecular Pathway in Autosomal Dominant Polycystic Kidney Disease. Journal of Personalized Medicine, 14(3),299.
(4) Meliţ, L. E., Mărginean, C. O., Mărginean, C. D., Mărginean, M. O., & Aldea, C. (2019). Neonatal polycystic kidney disease, a potential life-threatening condition at this age: a case report. Medicine, 98(44), e17707.
(5) Liebau, M. C. (2021). Early clinical management of autosomal recessive polycystic kidney disease. Pediatric Nephrology, 36(11),3561-3570.
(6) Skrajnowska, D., & Bobrowska-Korczak, B. (2024). The Effects of Diet, Dietary Supplements, Drugs and Exercise on Physical, Diagnostic Values of Urine Characteristics. Nutrients, 16(18), 3141.
(7) Burgmaier, K., Gimpel, C., Schaefer, F., & Liebau, M. (2024). Autosomal Recessive Polycystic Kidney Disease PKHD1GeneReviews®[Internet].
(8) Kleinová, P., Blichová, T., Graňák, K., Kollár, A., Vnučák, M., & Dedinská, I. (2024). Keto Analogues in Patients with Chronic Kidney Disease with or Without Kidney Transplantation. Nutrients, 16(23), (4001)
(9) Wilsdon, T., Axelsen, K., Poon, C., Petrova, A., & Zhang, R. (2025). The economic cost of living with a rare disease in Japan.
(10) van Spronsen, F. J., Blau, N., Harding, C., Burlina, A., Longo, N., & Bosch, A. M. (2021). Phenylketonuria. Nature reviews Disease primers, 7(1), 36.
(11) Rovelli, V., & Longo, N. (2023). Phenylketonuria and the brain. Molecular Genetics and Metabolism, 139(1), 107583.
(12) Elhawary, N. A., AlJahdali, I. A., Abumansour, I. S., Elhawary, E. N., Gaboon, N., Dandini, M., ... & Kensara, O. A. (2022). Genetic etiology and clinical challenges of phenylketonuria. Human genomics, 16(1), 22
(13) Vockley, J., Sondheimer, N., Puurunen, M., Diaz, G. A., Ginevic, I., Grange, D. K., ... & Brennan, A. M. (2023). Efficacy and safety of a synthetic biotic for treatment of phenylketonuria: a phase 2 clinical trial. Nature metabolism, 5(10), 1685-1690.
(14) Perez-Garcia, C. G., Diaz-Trelles, R., Vega, J. B., Bao, Y., Sablad, M., Limphong, P., ... & Chivukula, P. (2022). Development of an mRNA replacement therapy for phenylketonuria. Molecular Therapy-Nucleic Acids, 28, 87-98.
(15) Pinto, A., Ilgaz, F., Evans, S., van Dam, E., Rocha, J. C., Karabulut, E., ... & MacDonald, A. (2023). Phenylalanine tolerance over time in phenylketonuria: a systematic review and meta-analysis. Nutrients, 15(16), 3506.
(16) Yagudina, R., Kulikov, A., Serpik, V., Protsenko, M., & Kopeyka, K. (2024). Factors affecting adherence to a low phenylalanine diet in patients with phenylketonuria: A systematic review. Nutrients, 16(18), 3119.
(17) Vinueza, A. M. Z. (2023). Recent advances in phenylketonuria: A review. Cureus, 15(6).
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2025 The AuthorsHow to cite
10.3390/ani15040592